Food and Drug Administration (FDA) has given its approval for Boston Scientific Corp.'s Ion paclitaxel-eluting platinum chromium coronary stent
system and Taxus Liberte paclitaxel-eluting coronary stent
for use in patients experiencing an acute myocardial infarction (AMI), or heart attack.
A unique combination of a one-time short and precise drug delivery with DEB during placement of a coronary stent
is now for the first time approved and available in Europe.
Data collected by the Massachusetts Department of Public Health, which sponsored the study, on all patients who received a coronary stent
in the state showed that use of drug-eluting stents (DES) was associated with a significantly lower risk of death or need for revascularization and a similar incidence of myocardial infarctions, compared with patients treated with bare-metal stents (BMS), Dr.
The paclitaxel-coated coronary stent
program also entered human studies.
[USPRwire, Sun Nov 11 2018] Growing cases of coronary angioplasty (a treatment to widen narrowed sections of coronary arteries) is one of the key factors driving the demand for coronary stent
grafts in hospitals, surgical centers and emergency rooms.
A coronary stent
is a small cylindrical device used during percutaneous coronary intervention.
Navi Mumbai, India, March 07, 2015 --(PR.com)-- Market Reports on India presents the report on "Indian Coronary Stent
Market Forecast to 2019" the Indian market and the market trends, potential future growth areas, and challenges for the sector.
Healthcare company Abbott Laboratories (NYSE:ABT) announced on Thursday the receipt of US Food and Drug Administration's (FDA's) approval for its XIENCE Xpedition Everolimus Eluting Coronary Stent
The ION Paclitax-eleluting platinum chromium coronary stent
system is the company's third-generation drug-eluting stent technology.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, has announced at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent
have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".
The review included 5,342 patients at Prairie Heart who received their first drug-eluting coronary stent
during May 2003--December 2006.